Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline : evidence-based advances in monitoring and treatment. / de Boer, Ian H.; Caramori, M. Luiza; Chan, Juliana C.N.; Heerspink, Hiddo J.L.; Hurst, Clint; Khunti, Kamlesh; Liew, Adrian; Michos, Erin D.; Navaneethan, Sankar D.; Olowu, Wasiu A.; Sadusky, Tami; Tandon, Nikhil; Tuttle, Katherine R.; Wanner, Christoph; Wilkens, Katy G.; Zoungas, Sophia; Lytvyn, Lyubov; Craig, Jonathan C.; Tunnicliffe, David J.; Howell, Martin; Tonelli, Marcello; Cheung, Michael; Earley, Amy; Rossing, Peter.
I: Kidney International, Bind 98, Nr. 4, 10.2020, s. 839-848.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline
T2 - evidence-based advances in monitoring and treatment
AU - de Boer, Ian H.
AU - Caramori, M. Luiza
AU - Chan, Juliana C.N.
AU - Heerspink, Hiddo J.L.
AU - Hurst, Clint
AU - Khunti, Kamlesh
AU - Liew, Adrian
AU - Michos, Erin D.
AU - Navaneethan, Sankar D.
AU - Olowu, Wasiu A.
AU - Sadusky, Tami
AU - Tandon, Nikhil
AU - Tuttle, Katherine R.
AU - Wanner, Christoph
AU - Wilkens, Katy G.
AU - Zoungas, Sophia
AU - Lytvyn, Lyubov
AU - Craig, Jonathan C.
AU - Tunnicliffe, David J.
AU - Howell, Martin
AU - Tonelli, Marcello
AU - Cheung, Michael
AU - Earley, Amy
AU - Rossing, Peter
PY - 2020/10
Y1 - 2020/10
N2 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD.
AB - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeutics offer new options to manage the large population of patients with diabetes and chronic kidney disease (CKD) at high risk of poor health outcomes. An enlarging base of high-quality evidence from randomized clinical trials is available to evaluate important new treatments offering organ protection, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. The goal of the new guideline is to provide evidence-based recommendations to optimize the clinical care of people with diabetes and CKD by integrating new options with existing management strategies. In addition, the guideline contains practice points to facilitate implementation when insufficient data are available to make well-justified recommendations or when additional guidance may be useful for clinical application. The guideline covers comprehensive care of patients with diabetes and CKD, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and self-management and health systems approaches to management of patients with diabetes and CKD.
KW - angiotensin II receptor blocker
KW - angiotensin-convering enzyme inhibitor
KW - chronic kidney disease
KW - dialysis
KW - evidence-based
KW - GLP-1 receptor agonist
KW - glycemia
KW - glycemic monitoring
KW - glycemic targets
KW - guideline
KW - HbA1c
KW - hemodialysis
KW - KDIGO
KW - lifestyle
KW - metformin
KW - models of care
KW - nutrition
KW - renin-angiotensin system
KW - self-management
KW - SGLT2 inhibitor
KW - systematic review
KW - team-based care
U2 - 10.1016/j.kint.2020.06.024
DO - 10.1016/j.kint.2020.06.024
M3 - Journal article
C2 - 32653403
AN - SCOPUS:85089856232
VL - 98
SP - 839
EP - 848
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 4
ER -
ID: 257054337